• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

(C696-0726)

1

Identification

C696-0726 C696-0726
Name C696-0726
Formula C21H23N5O2
MW 377.44
CAS No.
EINECS
Smiles C1N=CC=C(CC2C3C=CC=CC=3C(N(CC(N3CCN(C)CC3)=O)N=2)=O)C=1
Synonyms
InChI InChI=1S/C21H23N5O2/c1-24-10-12-25(13-11-24)20(27)15-26-21(28)18-5-3-2-4-17(18)19(23-26)14-16-6-8-22-9-7-16/h2-9H,10-15H2,1H3
2

Introduction

C696-0726 is a novel cyclin-dependent kinase 8 (CDK8) inhibitor. The inhibition rate is 18.9±3.6% at 10 μM. CDK8 gene expression correlates with increased mortality in colorectal, breast, and ovarian cancers and its overexpression is essential for the proliferation of cancer cells. Due to its key roles in oncogenesis, CDK8 has recently attracted considerable attention. Inhibitors of CDK8 offer a novel strategy for the treatment of various cancers.

Background Information

3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB100692181

Storage condition

Solubility

5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
7

Safety Data of C696-0726

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AMEDCHEM CHINA
10

Related Products

Other Forms of

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

C696-0726

Tags: buy C696-0726 IC50 | C696-0726 price | C696-0726 cost | C696-0726 solubility | C696-0726 purchase | C696-0726 manufacturer | C696-0726 research buy | C696-0726 order | C696-0726 MSDS | C696-0726 chemical structure | C696-0726 Storage condition | C696-0726 molecular weight | C696-0726 mw | C696-0726 datasheet | C696-0726 supplier | C696-0726 cell line | C696-0726 NMR | C696-0726 MS | C696-0726 IR | C696-0726 solubility | C696-0726 Safe information | C696-0726 Qc and Spectral Information | C696-0726 Clinical Information | C696-0726 Clinical Trial | C696-0726 Route of Synthesis | C696-0726 storage condition | C696-0726 diseases and conditions | C696-0726 flash point | C696-0726 boiling point | C696-0726 melting point | C696-0726 storage condition | C696-0726 brand